4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

H.C. Wainwright initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $10.00

Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00

Total gross proceeds increased to $57.5 millionOffering consisted solely of common stockProceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028 AUSTIN, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the closing of its previously announced underwritten public offering of common stock, including the full exercise of the underwriters' over-allotment option. The financing included new and existing healthcare-focused investors

AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the pricing of its underwritten public offering of fifty million shares of its common stock at a public offering price of $1.00 per share for aggregate gross proceeds of $50 million, prior to deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 7.5M shares of common stock at the public offering

Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries 8 patients enrolled, with additional patients expected in the near termEnrollment initiated in March 2026, with patients being added on a regular basisClinical trial sites active in the United States, Australia, and Poland, with additional countries expected to open in the near term AUSTIN, Texas, April 29, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today provided an update on its ongoing Phase 2

AUSTIN, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that it has dosed the first patient in its Phase 2 clinical trial evaluating LTI-03 for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease with limited treatment options. This milestone follows the FDA's recent clearance to resume the Phase 2 program and reflects Rein's successful efforts to address the Agency's requests and advance the trial. The Phase 2 study is a randomized, double-blind, place

AUSTIN, Texas, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that it has received orphan drug designation from the European Medicines Agency (EMA) for LTI-03, its lead drug candidate aimed at preserving lung function in patients with idiopathic pulmonary fibrosis (IPF). The designation follows a positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP) and subsequent adoption by the European Commission, recognizing both the seriousness of IPF and the need for

AUSTIN, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that a new preprint has been posted to medRxiv describing clinical and translational findings from an inhaled, dose-escalation study of Rein's lead drug candidate, LTI-03, in idiopathic pulmonary fibrosis (IPF). The preprint, titled "Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation Study," was authored by an international team of investigators, including Philip L. Molyneaux, MD, Nikhil A. Hi

FDA lifts clinical hold following review of Company's Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites.Early data suggests that LTI-03 may not only slow fibrosis but also promote lung healing. AUSTIN, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the U.S. Food and Drug Administration (FDA) has lifted the full clinical hold on the Company's Phase 2 "RENEW" trial evaluating LTI-03 in patient

EMA approval covers study sites in Germany and Poland as part of the Company's global Phase 2 RENEW trialTrial will evaluate LTI-03, a first-in-class therapy designed to both reduce lung scarring and promote repair AUSTIN, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it has received authorization from the European Medicines Agency (EMA) to initiate the Company's Phase 2 "RENEW" clinical trial of its lead candidate, LTI-03, for the treatment of idiopathic pulmona

AUSTIN, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the publication of novel data on its lead drug candidate, LTI-03, in iScience, a peer-reviewed, open-access journal published by Cell Press. The paper, titled "LTI-03 peptide demonstrates anti-fibrotic activity in ex vivo lung slices from IPF patients," reports how LTI-03 was tested directly on lung tissue donated by patients with idiopathic pulmonary fibrosis (IPF) who underwent lung transplant. In this model, LT

AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Company to initiate its Phase 2 "RENEW" clinical trial of LTI-03, the Company's lead drug candidate for idiopathic pulmonary fibrosis (IPF). IPF is a serious, progressive lung disease that affects hundreds of thousands of people worldwide. It scars the lungs, leaving patients short of breath and with limited treatment options. Median

4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

3 - Rein Therapeutics, Inc. (0001420565) (Issuer)

4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

PRE 14A - Rein Therapeutics, Inc. (0001420565) (Filer)

10-Q - Rein Therapeutics, Inc. (0001420565) (Filer)

SCHEDULE 13G - Rein Therapeutics, Inc. (0001420565) (Subject)

8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

424B5 - Rein Therapeutics, Inc. (0001420565) (Filer)

S-1 - Rein Therapeutics, Inc. (0001420565) (Filer)

10-K/A - Rein Therapeutics, Inc. (0001420565) (Filer)

10-K - Rein Therapeutics, Inc. (0001420565) (Filer)

8-K - Rein Therapeutics, Inc. (0001420565) (Filer)

8-K - Rein Therapeutics, Inc. (0001420565) (Filer)